Skip to main content
Premium Trial:

Request an Annual Quote

Genaissance Posts Q4 Revenue Surge; R&D and Net Loss Grows

NEW YORK, Feb. 12 (GenomeWeb News) - Genaissance today posted a strong jump in fourth-quarter revenues atop increased R&D spending and a widened net loss.


Receipts for the three-month period ended Dec. 31 surged to $4.7 million from $2.6 million one year ago.


R&D spending, meantime, also increased in the fourth quarter to $6 million from $4.3 million in the year-ago period.


Net loss widened to $6.5 million, or $.28 per share, from $5.4 million, or $.24 per share, year over year, Genaissance said.


The company said it had around $16.8 million in cash, cash equivalents, and marketable securities as of Dec. 31.


Click here for more information.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.